Biogen

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market biological products for the treatment of serious diseases with a focus on neurological disorders.

Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates more than $4 billion in annual revenues.

Biogen, established in 1978 and headquartered in United States, North America., specializes in Late Stage Venture, Early Stage Venture investments across Biotechnology, Life Science, Medical, Financial Services, Venture Capital, Advice, Finance, Payments, Health Care, Medical Device. The organization boasts a portfolio of 29 investments, with an average round size of $64.1M and 17 successful exits. Their recent investments include Hydra Biosciences, Polaris Partners, Advanced Technology Ventures, MedImmune Ventures, Bioventures Investors. The highest investment round they participated in was $90.0B. Among their most notable exits are Hydra Biosciences and Polaris Partners. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.